Clear View Edge

TSG Consumer Partners LLC is a global leader in consumer-focused investing, managing approximately $13 billion in assets with a robust 35-year track record of building iconic brands. The firm collaborates closely with founders and management teams to enhance the growth, reach, and digital strategies of leading consumer brands across various sectors including health, wellness, food, and beauty. With a flexible investment approach, TSG engages in both minority and majority investments in established companies aiming to expand beyond their current successes. Their dedicated team leverages deep digital expertise and a network of trusted advisors to drive innovation and category-leading brand development. Generated from the website

Elga Wimmer PCC is a prominent art gallery located in New York, NY, specializing in contemporary art exhibitions. Led by curator Elga Wimmer, the gallery showcases a diverse range of artists and their thought-provoking works, exploring themes such as poverty, power, discrimination, and disenfranchisement. With a focus on creating meaningful narratives of human existence, Elga Wimmer PCC aims to foster a sense of community and respect through art. The gallery has featured renowned artists like Rodney Zelenka, whose recent exhibition "Dominion and Frailty" delves into the existential quandary of human life and the societal issues we face. Alongside Zelenka, Elga Wimmer PCC has also presented exhibitions by other notable artists such as Julius Deutschbauer, Gala Knoerr, Liliana Porter, Carolee Schneemann, Federico Solmi, Marina Vargas, and Wolf Vostell. Through their thought-provoking and visually captivating artworks, these artists address various social and political issues, creating a timeless impact through their high-caliber art.Generated from the website

New Leaf Venture Partners' objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. We are active investors and almost always serve as directors of our portfolio companies, who can draw upon perspectives and experiences of the entire NLV investment team and its network of successful scientists, clinicians, operating executives and entrepreneurs. We assist in building management teams, guiding corporate strategy, providing input to operating plans, and in making decisions about optimal paths for future financings and exits. As conditions evolve, NLV Partners team continually refines its differentiated strategy in healthcare investing. Both of NLV's latest funds, New Leaf Ventures I and New Leaf Ventures II, focus on taking leadership positions in: Biopharmaceuticals - NLV has an in-depth understanding of therapeutic targets and modalities, the drug R&D process, clinical trial design, regulatory requirements, and pharmaceutical commercial activities. NLV's extensive medical, clinical development, commercial and financial experience helps companies navigate the challenging path to regulatory approval and commercialization as stand-alone companies or through value-added strategic partnerships. NLV invests in companies at all stages in this sector, but looks at the level of risk, costs, and timelines to build real value in the underlying program (s) in determining if an investment fits our strategy. NLV has been particularly active in starting and investing in companies that been formed around the spin out of programs from larger pharmaceutical and biotech companies. Medical devices - NLV works closely with its network of entrepreneurs and scientific and medical founders to identify investment opportunities around promising technologies targeting areas of high unmet medical need and large commercial potential. The current strategy is to focus on later stage opportunities to provide growth capital or the last round to profitability in which regulatory and reimbursement risks are minimal. NLV will invest in early stage companies when there are large established global markets and an opportunity to prove safety and effectiveness in a focused, cost effective program. NLV's investment team brings critical operating experience and the ability to evaluate the biological, engineering, regulatory, reimbursement and market risks most relevant to starting, growing, developing and exiting young or more mature companies in the medical devices sector.